Why the study?
Does preemptive, targeted therapy with dexamethasone improve outcomes in a fetus at high risk of congenital complete heart block?
Does preemptive, targeted therapy with dexamethasone improve outcomes in a fetus at high risk of congenital complete heart block?
Preemptive dexamethasone therapy represents a potentially successful strategy for fetuses at high risk of congenital complete heart block.
May support preemptive dexamethasone in select high-risk fetuses; hypothesis-generating case report requiring prospective confirmation.
This represents a new and successful strategy to identify very early signs of myocardial disease in a fetus at high risk of congenital complete heart block, enabling targeted, preemptive therapy.
No takes yet. Share an insight, caveat, or question.
David N. Rosenthal (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: